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the host. In this report, we use a recently proposed framework to estimate the per capita killing efﬁcacy of
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result from the generation of an inefﬁcient PyV-speciﬁc CD8+ T cell response, and that other host or viral
factors are responsible for the ability of PyV to establish chronic infection.tic choriomeningitis virus; CIs,
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CD8+ T cells play an important role in controlling growth of viral
infections both in mice and humans by multiple mechanisms
including killing of virus-infected cells and production of antiviral
cytokines (Kaech et al., 2002; Wherry and Ahmed, 2004). Following
acute viral infections, CD8+ T cells follow a deﬁned program of
expansion, differentiation and contraction that results in clearance
of the virus within 1 to 2 weeks of the infection (Kaech and Ahmed,
2001; Badovinac et al., 2002; De Boer et al., 2003). During the
expansion phase, CD8+ T cells differentiate into effectors that possess
multiple functions and are very efﬁcient killers in vivo (Regoes et al.,
2007; Ganusov and De Boer, 2008). Although during a chronic viral
infection, such as LCMV clone 13 infection of mice, CD8+ T cells follow
a similar program of expansion and contraction (Wherry and Ahmed,
2004; Althaus et al., 2007), control of the virus is limited (Wherry and
Ahmed, 2004). Persistent viral load progressively leads to exhaustion
of antigen-speciﬁc CD8+ T cells which, over time, lose various effector
functions such as production of IL-2 and TNF-α (Wherry and Ahmed,2004). A similar progressive dysfunction of antigen-speciﬁc CD8+ T
cells has been observed during HIV infection (Streeck et al., 2008).
The reason why some infections are cleared and others persist is
unknown and is likely to be different for different infections. One
hypothesis is that persistent viruses elicit T cell responses of
inadequate quality which are unable to control viral growth during
the acute phase of the infection. Indeed, infection of mice with LCMV
clone 13 (persistent) elicits CD8+ T cell response of a lower
magnitude than during LCMV-Armstrong infection (acute). This may
be one reason why LCMV clone 13 persists in mice (Althaus et al.,
2007). Alternatively, a low effector to target cell ratio induced during
the infection with the rapidly replicating LCMV clone 13 may lead to
viral persistence (Li et al., 2009). Finally, persistence of LCMV clone 13
could be caused by a lower per capita killing efﬁciency of virus-
speciﬁc CD8+ T cells. As far as we are aware, there have been no
studies that attempted to discriminate between these different
mechanisms for the establishment of chronic viral infections. While
in vivo killing of peptide-pulsed targets by CD8+ T cell responses
during several chronic infections has been measured (Byers et al.,
2003; Fuller et al., 2004; Miller et al., 2005; Agnellini et al., 2007;
Frohlich et al., 2009), the per capita killing efﬁcacy of virus-speciﬁc
CD8+ T cells was not estimated.
Using a recently developedmethod of in vivo cytotoxicity (Aichele
et al., 1997; Oehen and Brduscha-Riem, 1998; Barchet et al., 2000;
Barber et al., 2003; Byers et al., 2003), we investigate whether
Fig. 1. Estimating the efﬁcacy of MT389-speciﬁc CD8+ T cells at killing targets, pulsed
with a high concentration of the peptide (≥1 μM), from the time series data. We ﬁt the
model prediction on the total number of unpulsed targets in the spleen (panel A, see
Eq. (1)) or the ratio of the frequency of peptide-pulsed to unpulsed targets R (panel B,
see Eq. (3)) to the data during acute (•) or chronic () phases of the PyV infection ofmice. Parameters providing the best ﬁt of the model to the data are given in Table 1.
Recruitment of targets into the spleen occurred similarly during the acute and chronic
phases of the infection (χ22=1.80, p=0.41). The half-life of peptide-pulsed targets at
the peak of the MT389-speciﬁc CD8+ T cell response is only 15 minutes, while during
the chronic phase, half of MT389-expressing targets were eliminated in 47 minutes.
Table 1
Parameter estimates obtained by ﬁtting the data on killing of targets that were pulsed
with a high concentration (≥1 μM) of the MT389 peptide. Here σ and δ are the rates of
recruitment of targets from the blood to the spleen or elsewhere, respectively, and k is
the per capita killing efﬁcacy of MT389-speciﬁc CD8+ T cells during acute (left) or
chronic (right) phase of the PyV infection of mice. The parameter was ﬁxed at 0 since it
did not affect the quality of the model ﬁt to data (LRT: χ12=2.32, p=0.13). The
estimated standard deviation of the errors in the ﬁt is s1=0.85 (0.64−1.04) and
s2=0.19 (0.13−0.23) (see Materials and methods for detail). The provided 95% CIs
were obtained by bootstrapping the data with 1000 simulations. Assuming that killing
depends on the number of MT389-speciﬁc CD8+ T cells in the spleen, the per cell killing
efﬁcacy was k=3.81×10−8 cell−1 min−1 and k=2.03×10−8 cell−1 min−1 in the
acute and chronic phases of the infection, respectively.
Parameter Acute Chronic
σ, 10−4min−1 3.96 (2.90–5.37)
δ, 10−3min−1 4.92 (2.95–7.04)
k, min−1 4.16 (3.42–4.84) 1.90 (1.65–2.18)
194 V.V. Ganusov et al. / Virology 405 (2010) 193–200infection of mice with polyoma virus (PyV) which causes a persistent
infection, elicits a CD8+ T cell response of a low killing efﬁcacy and
whether this killing efﬁcacy changes from the acute to chronic phase
of the infection. Unexpectedly, we found that the in vivo killing
efﬁcacy of PyV-speciﬁc CD8+ T cells at the peak of the immune
response is similar to that of LCMV-Armstrong-speciﬁc CD8+ T cells
obtained in previous studies (Yates et al., 2007, Ganusov et al., ms. in
preparation). This argues that the inability of the CD8+ T cell response
to clear PyV infection in the acute phase is not due to a low killing
efﬁcacy of antigen-speciﬁc T cells per se. Furthermore, during the
chronic phase of the infection, PyV-speciﬁc CD8+ T cells did not lose
their ability to kill evenmonths after the primary infection, being only
2 fold less efﬁcient killers than effectors present at the peak of the
immune response. Thus, even in the presence of an efﬁcient CD8+ T
cell response, PyV is able to establish a persistent infection in mice,
and it is likely that other viral and/or host factors play important roles
in this process. Our results also suggest that low expression of viral
proteins may have enabled PyV to establish a persistent infection in
mice.
Results
Estimation of the killing efﬁcacy of PyV-speciﬁc CD8+ T cells
We and others have previously developed a mathematical model to
estimate the death rates of peptide-pulsed targets in vivo due to CD8+ T
cell mediated killing and the per capita killing efﬁcacy of CD8+ T cells
(Regoes et al., 2007; Yates et al., 2007;Ganusov andDeBoer, 2008).Here,
we applied this model to estimate the per capita efﬁcacy of the
immunodominant polyoma virus (PyV)-speciﬁc CD8+ T cell response at
killing target splenocytes, pulsed with MT389 peptide of PyV during the
acute (day 7) or chronic (days 32–175) phases of the PyV infection of
mice (Vezys et al., 2006). Thismodel described the datawell (Fig. 1) and
estimated that half of peptide-pulsed targets are eliminated in
15 minutes in acutely infected mice and in 47 minutes during the
chronic phase of the infection. Both rates are surprisingly similar to those
obtained for targets expressing subdominant peptides from LCMV-
Armstrong (Ganusov and De Boer, 2008). Even more surprising, the per
capita killing efﬁcacy of MT389-speciﬁc effectors (k≈4.16 min−1) is
similar to the estimates obtained in previous studies for effector CD8+ T
cells, speciﬁc to the NP396 (k=5.5 min−1) or GP276 (k=2.35 min−1)
epitopes of LCMV-Armstrong (see Table 1 andYates et al., 2007,Ganusov
et al., ms. in preparation). We ﬁnd that the per capita killing efﬁcacy of
CD8+ T cells in the chronic phase of the infection was only half of the T
cell efﬁcacy during the acute infection (Fig. 1). The change in the killing
efﬁcacy from the peak of the CD8+ T cell response to the chronic phase
was highly signiﬁcant (LRT: χ12=57.11, p≪0.01).
We found that recruitment of target cells from the blood into the
spleen occurred at similar rates in the acute and chronic phases of the
PyV infection (Fig. 1 and Table 1; χ22=1.80, p=0.41). Approximately
5% of transferred unpulsed targets accumulated in the mouse spleen
at 4 hours consistent with previous estimates (Blattman et al., 2002;
Ganusov and De Boer, 2008). The half-life time of targets in the blood
as determined by the rate of removal of targets from the blood,
d=δ+σ+ , was estimated at t1/2≈2 hours also consistent with a
previous estimate (Ganusov and De Boer, 2008). Interestingly, in this
study we did not ﬁnd evidence of the preparation-induced death of
targets (=0, χ12=2.32, p=0.13), which is in contrast with our
previous observations for LCMV-Armstrong infection (Ganusov and
De Boer, 2008, Ganusov et al., ms. in preparation). The different
methods of preparing single cell suspensions in the two laboratories
and the type of infections may have contributed to the observed
difference in estimates of this parameter.
To further conﬁrm our estimates of the killing efﬁcacy of PyV-
speciﬁc CD8+ T cells, we used a previously proposed protocol and
calculated theminimal andmaximal estimates of the killing efﬁcacy atvarious times after target cell transfer (Ganusov and De Boer, 2008 see
also Materials and methods). The killing efﬁcacy estimates are fairly
consistent for all time points analyzed for chronically infected mice
but not for acutely infected mice (Fig. S1 in Supplementary
information). The latter is most likely due to errors associated with
recovering a small number of remaining peptide-pulsed targets at the
end of the killing assay. Importantly, there is a considerable overlap
between estimates of the killing efﬁcacy of T cells in the acute and
chronic phases of the PyV infection. This conﬁrms the time series data
analysis which showed that on average, killing efﬁcacy of the MT389-
speciﬁc T cell response in chronic phase of the infection is only two
fold lower than that of PyV-speciﬁc T cells in the acute phase (Fig. 1
Fig. 3. Estimating the killing efﬁcacy of the PyV-speciﬁc CD8+ T cells in acute (—) and
chronic (- - -) phases of the infection from single measurements of killing. Points
represent the maximal killing efﬁcacy of MT389-speciﬁc CD8+ T cells, estimated for
individual mice, and horizontal lines are averages for a given peptide concentration.
Solid lines show the ﬁts of a Hill function given in Eq. (6) with n=1 to the estimated
killing efﬁcacies. The estimated parameters are: kˆ = 4:34min−1, h=0.12 μM (acute)
and kˆ = 1:91min−1, h=0.008 μM (chronic). Differences in kˆ and h for cells in the
acute and chronic phases of the infection remained if we used the minimal estimate of
the killing efﬁcacy (results not shown).
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killing efﬁcacy of MT389-speciﬁc CD8+ T cells during the chronic
phases of the infection (Fig. 2) suggesting that long-term exposure to
a persistent infection need not result in the loss of in vivo effector
functions. This result is consistent with the previous observation that
CD8+ T cells are mainly maintained by the production of effector T
cells from newly recruited naive PyV-speciﬁc T cells in chronic PyV
infection (Vezys et al., 2006). Nevertheless, this contrasts the data on
chronic LCMV infection during which shows that LCMV-speciﬁc CD8+
T cells lose some of their effector functions such as production of IL-2
and TNF-α over time (Wherry et al., 2003). Whether LCMV-speciﬁc
CD8+ T cells lose their in vivo killing efﬁcacy over time of chronic
infection remains to be investigated.
Killing efﬁcacy at different peptide concentrations
It has been shown that the number of targets killed in the in vivo
cytotoxicity assay depends strongly on the peptide concentration used to
pulse target cells (e.g., Byers et al., 2003). However, it has not been
investigatedhowthis translates into thekillingefﬁcacyofpeptide-speciﬁc
CD8+ T cells and whether there is a difference in the killing efﬁcacy of T
cells over the course of a chronic infection at low peptide concentrations.
To investigate how the killing efﬁcacy of CD8+ T cells depends on the
concentration of the peptide used to pulse target cells, we use two
approaches. First, we estimated the per capita killing efﬁcacy of MT389-
speciﬁc T cells for every mouse from a single measurement of killing
using Eqs. (4)–(5). As expected, the killing efﬁcacy of CD8+ T cells was
higher when targets were pulsed with a higher peptide concentration
(Fig. 3). Surprisingly, we ﬁnd little difference in the killing efﬁcacy of
MT389-speciﬁc CD8+ T cells in the acute and chronic phases of the
infection when the peptide concentration was low. In fact, at the lowest
peptide concentration (0.001 μM), MT389-speciﬁc CD8+ T cells in the
chronic phase appeared to be more efﬁcient at clearing peptide-pulsed
targets than PyV-speciﬁc CD8+ T cells in the acute phase of the infection
(Fig. 3). In contrast, T cells in the acutephaseweremoreefﬁcient at killing
targets than PyV-speciﬁc T cells in the chronic phase at high peptide
concentrations, as expected from the above analysis (see Table 1).
Second, we reﬁt the time series data on killing of targets pulsed
with peptides at different concentrations assuming that killing
efﬁcacy of CD8+ T cells depends on the amount of peptide that target
cells present (see Eq. (6)). The model described the data reasonablyFig. 2. The per capita killing efﬁcacy of PyV-speciﬁc CD8+ T cells does not change during
the chronic phase of the infection. We estimate the killing efﬁcacy of MT389-speciﬁc
CD8+ T cells from the cytotoxicity assay by normalizing the death rate of peptide-
pulsed targets Kmax by the average frequency of epitope-speciﬁc CD8+ T cells in the
spleen fE, kmax=Kmax/fE (see Materials and methods). Bars show the average estimate
per time point. The regression slope is not signiﬁcantly different from zero (F-test,
p=0.17 with one outlier with a low estimate for kmax removed). The independence of
the killing efﬁcacy of CD8+ T cells in the chronic phase of the infection from the time
since infection was further conﬁrmed by ﬁtting longitudinal killing data (as in Fig. 1B)
as the ﬁt was not signiﬁcantly improved by assuming that killing efﬁcacy was different
for different days during the chronic phase of the infection (F-test for nested models,
F4,16=2.06, p=0.13; results not shown).well (Fig. 4) with the exception of the datawith peptide concentration
0.01 μM where the model underestimated the amount of killing
(Fig. 3). Interestingly, the model ﬁts also predicted a lower half-
saturation constant h (i.e., a higher afﬁnity to the antigen) of MT389-
speciﬁc CD8+ T cells in the chronic phase of the infection than that of
cells in the acute phase (Table 2 and Fig. S2 in Supplementary
information). A higher killing efﬁcacy of CD8+ T cells in the acute
phase at high concentrations of the MT389 peptide has also been
conﬁrmed by this analysis (Table 2).CD8+ T cell and PyV dynamics
From the in vivo cytotoxicity assay we have found that targets
pulsed with a high concentration of MT389 peptide (≥1 μM) were
killed at the peak of the MT389-speciﬁc CD8+ T cell response at a very
high rate (half-life time t1/2≈ 15 min, Table 1 and Fig. 1). The next
step is to estimate the death rate of PyV-infected cells due to killing by
the PyV-speciﬁc CD8+ T cell response. It was not yet possible to
adoptively transfer PyV-infected epithelial cells (the major cell target
of PyV, Krumbholz et al., 2009) to measure their killing. As an
alternative approachwe correlated changes in the PyV load in infected
mice with the CD8+ T cell response using a mathematical model.
More speciﬁcally, the model was ﬁtted to the data on the dynamics of
the PyV-speciﬁc CD8+ T cell response and PyV load in the mouse
spleen (see Materials and methods for more details). The model
predicted a rapid increase of the number of MT389-speciﬁc CD8+ T
cells in the spleen with an average doubling time of ln2/
1.65 day≈10 hours (Fig. 5). The rapid increase in the number of
MT389-speciﬁc CD8+ T cells led to a decline in the virus density in the
spleen at the rate K≈1.89 per day (half-life time t1/2=8.8 hours).
Assuming that the decline in the virus density is caused solely by
MT389-speciﬁc CD8+ T cells, the estimated per cell efﬁciency of
MT389-speciﬁc CD8+ T cells at killing PyV-infected cells is k≈K/
E=6×10−10 cell−1 min−1 (Fig. 5). This value is approximately 50
times lower than the killing efﬁcacy of MT389-speciﬁc CD8+ T cells at
killing targets pulsed with a high concentration of the MT389 peptide
(see Table 1). Lower killing efﬁcacy of T cells at killing PyV-infected
cells implies that in vivo expression of the MT389 peptide on the cell
surface of infected cells is on the order of 10−2 μM which is very low
(see Fig. S2). Therefore, low expression of viral proteins may have
allowed PyV to escape recognition by the efﬁcient PyV-speciﬁc T cell
response and to establish a persistent infection.
Fig. 4. Estimating the efﬁcacy of PyV-speciﬁc CD8+ T cells at killing target cells, pulsed with different concentrations of peptide MT389, from the time series data. Points are the
measured ratios of the frequency of peptide-pulsed to unpulsed target cells, and lines show the ﬁts of the model prediction to the data. The data were ﬁtted simultaneously assuming
that the dependence of the killing efﬁcacy on the peptide concentration follows a Hill function (see Eq. (6)). Parameters providing the best ﬁt of themodel to data are given in Table 2.
Note that to show the ﬁts and the data, we used different scales on y-axes.
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PyV-infected cells by the PyV-speciﬁc CD8+ T cell response is themain
mechanism of PyV replication in the acute phase of the infection. A
recent study, however, indicates that while CD8+ T cells are
important to prevent generation of PyV-induced tumors in B6 mice,
perforin is not required for the early control of PyV replication (Byers
et al., 2007). Furthermore, recent work indicates a potential role of
IFN-γ is suppression of replication of polyomaviruses (Abend et al.,
2007, J. J. Wilson and A. E. Lukacher (unpublished)). Therefore, we
investigated if nonlytic control of PyV replication can explain the data
on the dynamics of PyV andMT389-speciﬁc CD8+ T cell response (see
description of the model in Materials and methods and Fig. S4 in
Supplementary information). The model could describe the data very
well and predicted loss of PyV-infected cells due to viral pathogene-
city at the rate ∼3 day−1 implying a relatively short average life-span
for infected cells (1/δ≈8 hours). On the other hand, the MT389-
speciﬁc CD8+ T cell response is estimated to be moderately efﬁcient
since it reduced the rate of virus replication only by 3 fold at the peakTable 2
Parameter estimates obtained by ﬁtting the data on killing of targets that were pulsed
with different concentrations of theMT389 peptide. The data were ﬁtted as described in
the legend of Fig. 4, assuming different maximal killing efﬁcacies during acute and
chronic phases of the infection (kˆ) and different half-saturation constants (h, see Eq. (6)
in Materials and methods). Importantly, the half-saturation constant was different for
CD8+ T cells in acute and chronic PyV infection (F-test for nested models, F1,61=4.7,
p=0.034). The shape parameter of the Hill function n was not signiﬁcantly different
from 1 (F-test for nestedmodels, F1,60=3.57, p=0.064). Assuming that killing depends
on the total number of MT389-speciﬁc CD8+ T cells in the spleen, we ﬁnd the per cell
killing efﬁcacy kˆ = 3:6 × 10−8 cell−1min−1 and kˆ = 1:9 × 10−8 cell−1min−1 during
acute and chronic phases, respectively.
Parameter Acute Chronic
d, 10−3min−1 5.83 (3.61–8.78)
kˆ; min−1 3.50 (2.93–4.04) 1.89 (1.58–2.16)
h, μM 0.19 (0.10–0.37) 0.08 (0.04–0.14)of the response. Thus, the model with nonlytic control of virus
replication also predicts a poor efﬁcacy of PyV-speciﬁc CD8+ T cell
response in suppressing PyV replication in vivo.
Discussion
There is limitedunderstandingofwhyCD8+Tcell responses in some
cases can control and clear viral infections while in other cases they fail
to do so. It was recently shown that the initial effector to target ratio
during the acute phase of LCMV infection may determine whether theFig. 5. The dynamics of MT389-speciﬁc CD8+ T cells and the viral load in spleens of mice
infectedwith PyV. Points show the data, and lines are the predictions of the mathematical
model. For the CD8+ T cell response, we obtain the following estimates of the model
parameters (see Materials and methods for more detail): the initial number of naive
MT389-speciﬁc CD8+ T cells in the spleen A0=143, the rate of expansion ρ=1.65 day−1,
the rate of apoptosis of activated T cells δA=0.10 day−1, the rate of reversion of activated
cells into the resting state δr=0.02 day−1, and the time for the predicted peak of the
response Toff=6 days. For the virus dynamics, we obtain the following estimates of the
model parameters: the initial viral density V0=3.1×103 PFU/g, the rate of virus
replication r=0.15 day−1, the killing efﬁcacy of MT389-speciﬁc CD8+ T cells
k=8.64×10−3 cell−1 day−1 (or k=6×10−10 cell−1 min−1), and the limit of detection
of 2.2 PFU/g.
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2009). Our results demonstrate that in the case of PyV infection of mice,
the failure to clear the infection is not due to a reduced killing efﬁcacy of
PyV-speciﬁc CD8+ T cells per se. Instead we found that the killing
efﬁcacyof PyV-speciﬁc effectors is similar to that of LCMV-speciﬁc CD8+
T cells which clear the LCMV-Armstrong infection from mice within
7 days (Lau et al., 1994). Othermechanisms, such as the ability to persist
in a silent form by expressing proteins at a low level, may have allowed
PyV toescape theeradication from infectedmice. This is supportedbyan
observation that the loss rate of PyV-infected cells is much smaller than
theestimated loss rate of targets, pulsedwithahigh concentrationof the
MT389 peptide (t1/2=8.8 hours vs. t1/2=15 min, respectively). It
would be interesting to investigate if infection of mice with other
strains of LCMV, someofwhich induce high levels of IL-10 (Ejrnaes et al.,
2006; Brooks et al., 2006; Maris et al., 2007), establishes persistence by
reducing the killing efﬁcacy of LCMV-speciﬁc CD8+ T cells and not
necessarily due to a low ratio of effectors to targets (Li et al., 2009). It is
important to emphasize that even though killing of peptide-pulsed
targets has been measured during chronic LCMV infection (e.g., Fuller
et al., 2004; Miller et al., 2005; Agnellini et al., 2007), the per capita
killing efﬁcacy of LCMV-speciﬁc CD8+ T cells has not been estimated.
We focused our analysis on the kinetics and killing efﬁcacy of the
immunodominant MT389-speciﬁc CD8+ T cell response. The subdom-
inant, MT127-speciﬁc CD8+ T cell response has at least 10-fold lower
killing efﬁcacy (see Fig. S3 in Supplementary information) and thusmost
likely does not signiﬁcantly contribute to the control of PyV replication.
We found that PyV-speciﬁc CD8+ T cells during the chronic phase of
the infection have a lower half-saturation constant for killing than T cells
present at the peak of the immune response (Table 2 and Fig. S2 in
Supplementary information). A lower half-saturation constant suggests
that these CD8+ T cells are more sensitive to lower quantities of the
antigen than effectors. The effect of T cell receptor downregulation on T
cells, thereby reducing TCR avidity to the antigen (“tuning of activation
threshold”) has been proposed to occur in some situations, for example,
during maturation of T cells in the thymus (Grossman and Paul, 1992;
Grossman and Singer, 1996), and has been documented to occur during
acute infections (Slifka andWhitton, 2001; Zehn et al., 2009). Our results
indicate that CD8+ T cells may also regulate their avidity for the antigen
when antigen load is low. In the acute phase, when antigen is abundant,
CD8+T cellswith lower avidity are selected. In the chronic phase, CD8+T
cells with higher avidity may become dominant to efﬁciently control
virus replicationwhen antigen is limited. Such a selection could occur via
at least twomechanisms. First, higher avidity T cellsmaybe selected from
the existing pool of effector T cells during the chronic phase of the
infection.Alternatively, PyV-speciﬁcnaiveCD8+Tcells thathave recently
emigrated from the thymus and have a high afﬁnity forMT389 epitope of
PyV could be preferentially activated by the low amount of antigen
present during the chronic phase of the infection (Vezys et al., 2006).
Given the inability of PyV-speciﬁc CD8+ T cells to self-renew during the
chronic phase of the infection (Vezys et al., 2006), the latter mechanism
seems more likely. One potential way that a cell can regulate avidity for
the antigen is the number of T cell receptors present on the cell surface. A
testable prediction of our analysis would be a higher number of T cell
receptors on PyV-speciﬁc CD8+ T cells during the chronic phase of the
infection as compared to effectors at the peak of the immune response.
In contrast to the substantial body of work characterizing memory
CD8 T cell exhaustion in high-load chronic viral infections, surpris-
ingly little is known about maintenance of memory CD8+ T cells to
viruses that establish low-level persistent infection. Persistent viremia
(i.e., high-load persistent infection) is associated with a number of
infections of global importance, including HIV, HCV, and HBV. In mice,
infection by high replicating strains of LCMV (e.g., clone 13 or DOCILE)
has been the principal animal model for high-load persistent
infection. In this setting, LCMV-speciﬁc CD8+ T cells progressively
accumulate defects in effector function and replication potential and
are then deleted, a phenomenon called “exhaustion” (Zajac et al.,1998; Wherry and Ahmed, 2004; Wherry et al., 2007). The high
antigenic burden and duration associated, for example, with HIV
infection also drives virus-speciﬁc CD8+ T cells to exhaustion and is
generally considered to be a prelude to viral persistence (Streeck et al.,
2008; Rowland-Jones and de Silva, 2008). T cell exhaustion, however,
is at odds to situations involving low-load persistent viral infections
(e.g., γHV-68 or PyV in mice) where the majority of CD8+ T cell
functions as measured in ex vivo assays are not compromised and
stable numbers of virus-speciﬁc T cells are maintained (Kemball et al.,
2005; Obar et al., 2006; Cush et al., 2007; Cush and Flano, 2009). Here
we further demonstrate that the in vivo killing efﬁcacy of PyV-speciﬁc
CD8+ T cells in the chronic phase of the infection is only two fold
lower than that of cells in the acute phase. This argues that CD8+ T
cells can maintain their in vivo effector functions long after the
primary phase of a persistent infection (Fig. 2).
We have found that killing efﬁcacy of PyV-speciﬁc CD8+ T cells
depended strongly on the peptide concentration used to pulse targets.
To kill a peptide-pulsed target, a CD8+ T cell must accomplish two
tasks: ﬁnd the target and deliver the lethal hit. It is unclear which of
these two processes is the limiting step in the killing of targets.
Additional studies including those looking at the process of killing of
targets by effector T cells in vivo (e.g., Mempel et al., 2006) would be
necessary to investigate this issue further.
While killing may be important in the control of replication of many
viruses, its role in the control of replication of polyomaviruses is not
completely understood. Recent work suggests that perforin is not
required for the initial control of PyV replication in B6 mice, although in
the chronic infection (N40 days post infection), viral loads are higher in
some peripheral organs such as lung and heart in perforin-knockout
than in controlmice (Byers et al., 2007). IFN-γ can suppress replicationof
polyomaviruses in vitro (Abendet al., 2007) but its effects in vivo are less
well understood. Based on these data, we also formulated an alternative
model that describes PyV-speciﬁc CD8+ T cell control of acute and
persistent infection via a nonlytic effector mechanism (e.g., by reducing
the rate of virus production by infected cells; see Materials and
methods). The model suggests that nonlytic control of PyV replication
by CD8+ T cells is consistent with the data but also predicts low efﬁcacy
ofMT389-speciﬁcCD8+Tcells in suppressionof PyVgrowth in vivo. This
is in line with our analysis of the killing efﬁcacy of PyV-speciﬁc T cells.
Overall, our analysis suggests that PyV-speciﬁc CD8+ T cells are
highly efﬁcient killers of peptide-pulsed targets in vivo. However, we
show that such potent killing efﬁcacy does not translate into efﬁcient
killing of virus-infected cells (or into efﬁcient nonlytic suppression of
virus replication in vivo). Such low efﬁciency at killing/suppression of
virus-infected cells could arise via a number of mechanisms. One
possibility is expression of inhibitory molecules by PyV-infected cells
that prevent lysis of these cells by PyV-speciﬁc T cell response.
Alternatively, release of immunosuppressive cytokines (e.g., IL-10
or TGF-β) by infected cells or bystander cells activated by virus-
associated inﬂammation, as well as expansion of regulatory T cells
could lead to a low efﬁcacy of PyV-speciﬁc CD8 T cells in control of PyV
replication in vivo. Finally, we propose that by the peak of the CD8+ T
cell response, PyV-infected cells express low levels of viral proteins
and this enables the virus to escape complete clearance and establish
a persistent infection. It should be noted, however, that all of these
mechanisms are speculative at this point with respect to the mouse
PyV infection model and require additional investigations.
Materials and methods
Data
Themethodofmeasuring cytotoxicity of CD8+T cells in vivohas been
described indetail elsewhere (Ingulli, 2007;Ganusov andDeBoer, 2008).
Here, we reanalyze recently published data on killing of peptide-pulsed
splenocytes by polyoma virus (PyV)-speciﬁc CD8+ T cells during acute
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2003). The reader is referred to the original publication formore detail. In
short, target splenocytes were pulsed with the MT389 peptide of PyV or
were left unpulsed. The peptide MT389 was chosen because it elicits the
dominant CD8+ T cell response in H-2k (C3H) mice (Lukacher et al.,
1999). Cells were transferred into syngeneic mice either infected with
PyV for 7 days (“acute” phase), or into mice controlling PyV infection
(days 35–175 post infection, “chronic” phase). Seven days after the
infection, the CD8+ T cell response to PyV reaches its peak then largely
contracts by 30 to 40 days after the infection (Vezys et al., 2006, see
Fig. 5). At various times after the transfer of target cells (15 min, 30 min,
1 hour, 2 hours, and 4 hours), spleenswere harvested, and the number of
pulsed and unpulsed target cells, splenocytes, and peptide-speciﬁc CD8+
T cells were measured. To investigate how the killing efﬁcacy of MT389-
speciﬁcCD8+Tcellsmaybeaffectedby thepeptide concentrationused to
pulse targets, target splenocytes were pulsed with 5 different concentra-
tions of the MT389 peptide (10, 1, 0.1, 0.01, and 0.001 μM) and killing of
peptide-pulsed targets was measured as described above.
To estimate the per capita killing efﬁcacy of MT389-speciﬁc CD8+ T
cells, we used either the average frequency or the average number of
these cells in spleens of PyV-infected mice. Our previous analyses
suggested that the frequency or the number of LCMV-speciﬁc CD8+ T
cells in spleensof individualmice bears little information on thenumber
of target cells killed in the same mouse (Ganusov at al., ms. in
preparation). In our experiments, we found that using average
frequencies or average numbers of MT389-speciﬁc CD8+ T cells in all
mice rather than values measured in individual mice also gave a better
ﬁt of the data (results not shown). As in our previous work, this is likely
because measurements of CTL frequencies were noisy and poorly
correlated with the number of targets killed. Because killing occurs in a
solidorgan such as the spleen, it follows fromgeneral physical principles
that killing of targets should depend on the frequency of the epitope-
speciﬁc CD8+T cells (Regoes et al., 2007).However, direct experimental
evidence of whether killing depends on the frequency of killers or their
total number is still lacking (Ganusov et al., ms. in preparation).
Therefore, we used the average frequency or the total number of
MT389-speciﬁc CD8+ T cells in the spleen to ﬁt the data and report the
per capita or per cell killing efﬁcacy k, respectively. In our experiments,
the average frequency ofMT389-speciﬁc CD8+T cells in the acute phase
was fE=1.13% (with standard deviation SD=0.21%, n=16), and in the
chronic phase was fE=0.79% (SD=0.15%, n=22). The total number of
MT389-speciﬁc CD8+ T cells in the spleen was E=1.23×106 (with
SD=0.39×106, n=16) and E=0.73×106 (with SD=0.23×106,
n=22) in the acute and chronic phases, respectively.
We have previously found that the rate of recruitment of target cells
into the spleen in LCMV-infectedmicewas correlatedwith the spleen size
(GanusovandDeBoer, 2008). For PyV-infectedmice, a similar correlation
was found although it was not statistically signiﬁcant (results not
shown). Therefore, to simplify the analysis we assumed that recruitment
of target cells into the spleen occurs at the same rate σ in all mice. To
model the dynamics of MT389-speciﬁc CD8+ T cell response to PyV
infection in C3H mice, we used published data (Lukacher et al., 1999).
Mathematical model for the cytotoxicity in vivo assay
We have extended a previously proposedmodel to quantify killing
efﬁcacy of CD8+ T cells from the in vivo cytotoxicity assay (Regoes
et al., 2007; Yates et al., 2007; Ganusov and De Boer, 2008). In this
model, peptide-pulsed and unpulsed (control) targets are injected
intravenously and from the blood migrate to different organs
including spleen. The rate of target cell migration to the spleen is σ
and migration to other organs (or death in the blood) occurs at the
rate δ. Cells in the blood and the spleen also die due to preparation of
single cell suspensions at the rate  that is independent of CD8+ T cell
mediated killing. In the spleen, peptide-pulsed targets are killed by
the peptide-speciﬁc CD8+ T cells at the rate K. In the case when allthese rates are constant, changes in the number of unpulsed and
peptide-pulsed targets in the mouse spleen are given by the following
equations (Ganusov and De Boer, 2008):
SðtÞ = c
d− e
−t−e−dt
h i
; ð1Þ
TðtÞ = cð + K−dÞ e
−dt−e−ð + KÞt
h i
; ð2Þ
where d=σ++δ is the rate of removal of cells from the blood, σ
and δ are the rates of recruitment of targets from the blood into the
spleen or elsewhere, respectively,  is the rate of preparation-induced
cell death, and c=SB(0)σ with SB(0)=5×106 (the initial number of
targets adoptively transferred into mice). Dividing Eq. (2) by (1) we
arrive at the experimentally measured ratio of peptide-pulsed to
unpulsed targets, R(t)=T(t)/S(t)
RðtÞ = ðd−Þ
K−ðd−Þ
e−ðd−Þt−e−Kt
1−e−ðd−Þt
" #
e−t : ð3Þ
Note that the dynamics of the ratio R(t) is determined only by K, 
and d− , but in general only K and d− can be determined from the
experimentally measured changes in the ratio R over time (Ganusov
and De Boer, 2008, see also Fig. 1). Knowing the dynamics of unpulsed
targets in the spleen allows us to determine all model parameters. To
estimate the per capita killing efﬁcacy of PyV-speciﬁc CD8+ T cells, we
let k=K/fE where k is the per capita killing efﬁcacy and fE is the
frequency of MT389-speciﬁc CD8+ T cells in the mouse spleen (or
k=K/E where E is the total number of MT389-speciﬁc CD8+ T cells if
killing is number-dependent). Using adoptive transfer of LCMV-
speciﬁc effectors or memory T cells, we have recently shown that
killing of peptide-pulsed targets is proportional to the magnitude of
the CD8+ T cell response in the spleen (Ganusov et al., ms. in
preparation). Although a similar type of information is lacking for PyV
infection of mice, for the following analysis, we assume that the death
rate of peptide-pulsed targets K in the spleen is proportional to the
average frequency (or average number) of epitope-speciﬁc CD8+ T
cells in the acute and chronic phases of the infection.
In our analysis, we also estimate the maximal (Kmax) and minimal
(Kmin) death rates of peptide-pulsed targets due toCD8+Tcellmediated
killing from the in vivo cytotoxicity experiments (Ganusov and De Boer,
2008). Kmax is estimated by solving the transcendental equation,
Kmax =
ð1−e−KmaxtÞ
Rt
; ð4Þ
and Kmin is estimated from
Kmin = −
logR
t
; ð5Þ
where R is the ratio of the frequency of peptide-pulsed to unpulsed
targets in the spleen at time t after target cell transfer. The per capita
killing efﬁcacy of CD8+ T cells k is then calculated by dividing the
death rate of peptide-pulsed targets K by the frequency fE (or number
E) of peptide-speciﬁc CD8+ T cells in the mouse spleen (assuming the
mass-action killing, see above).
The dependence of the killing efﬁcacy of CD8+ T cells on the
peptide concentration used to pulse target cells was taken in the form
of a Hill function,
k =
kˆpn
hn + pn
; ð6Þ
where kˆ is the maximal killing efﬁcacy of MT389-speciﬁc CD8+ T
cells, p is the peptide concentration used to pulse target cells, h is the
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power of the Hill function.
Mathematical model for the CD8+ T cell response and PyV dynamics
To describe the dynamics of MT389-speciﬁc CD8+ T cell response
in the spleen (Lukacher et al., 1999), we use a simple mathematical
model (De Boer et al., 2001, 2003; Antia et al., 2005; Ganusov et al.,
2007; Althaus et al., 2007). Themodel assumes that a small number of
naive, epitope-speciﬁc CD8+ T cells (A0) are activated following
infection and their population expands at the rate ρ. After the peak of
the T cell response that occurs at t=Toff, activated T cells (A) either die
at rate δA or convert into resting effector/memory T cells (M) at rate δr.
The model for the T cell response is then given by the following
equations:
dA
dt
= f ðtÞρA−ð1−f ðtÞÞðδA + δrÞA; ð7Þ
dM
dt
= ð1−f ðtÞÞδrA; ð8Þ
where f(t) is a step function with properties f(t)=1 if tbToff and 0,
otherwise. We let naive cells become activated and start proliferating
at the beginning of infection. More realistically, naive precursor cells
should start proliferating after they have been recruited through
antigenic stimulation. However, since our data do not include the
early dynamics of MT389-speciﬁc CD8+ T cells, such a simpliﬁcation is
justiﬁed.
To describe the dynamics of PyV we extend a model previously
suggested for the dynamics of human immunodeﬁciency and
hepatitis C viruses (Perelson et al., 1996; Neumann et al., 1998)
with the dynamics of the PyV-speciﬁc CD8+ T cell response:
dT
dt
= dðT0−TÞ−βVT; ð9Þ
dI
dt
= βVT−ðδ + kðA + MÞÞI; ð10Þ
dV
dt
= pI−cV ; ð11Þ
where V is the density of free virus, I is the density of PyV-infected
cells, T and T0 is the density of uninfected cells at time t and in the
absence of infection, respectively, d is the rate of turnover of
uninfected cells, β is the infection rate of uninfected cells by free
virus, δ is the death rate of virus-infected cells, p is the production rate
of free virus by virus-infected cells, c is the death rate of free virus and
k is the per cell killing efﬁcacy of the PyV-speciﬁc CD8+ T cell
response. Assuming that free virus is short-lived (c≫δ), the density
of the virus is proportional to the density of infected cells, V≈pI/c
(Perelson et al., 1996). Because we only focus on the virus dynamics
close to the peak of the T cell response (e.g., see Fig. 5), we can further
simplify the model Eqs. (9)–(11) by assuming a constant level of
target cells T*. Changes of free viral particles V over time are given by
dV
dt
= rV−kVE; ð12Þ
where r=βT*p/c−δ is the net rate of viral growth in the absence of T
cell response. Since there is a small difference in the per cell killing
efﬁcacy of MT389-speciﬁc CD8+ T cells in the acute and chronic
phases (see main text), the use of a single killing efﬁcacy k in Eq. (12)
is justiﬁed. The killing of virus-infected cells by the PyV-speciﬁc CD8+
T cell response follows the law of mass-action (Ganusov et al., ms. in
preparation).We have also extended themodel given in Eqs. (9)–(11)
by assuming that CD8+ T cells control viral growth by preventinginfection of target cells or by reducing the rate of virus production by
infected cells (e.g., Ganusov and De Boer, 2006). Both mechanisms,
assuming a short life-span of free virus, will result in the following
model for the PyV dynamics in the mouse spleen:
dV
dt
=
rV
1 + aE
−δV ; ð13Þ
where a is the per cell suppressive efﬁcacy of PyV-speciﬁc CD8 T cells.
Statistics
In our previous study (Ganusov and De Boer, 2008), we assumed
that measurement errors of the number of unpulsed targets in the
spleen and of the ratio of the frequency of peptide-pulsed to unpulsed
targets peptide-pulsed targets were of a similar magnitude. In PyV-
infected mice, this clearly was not the case since there was a
signiﬁcantly larger error in estimating the number of targets recruited
than the error in the percent of targets killed (see Fig. 1). To account
for different errors inmeasurements of target cell recruitment and cell
killing, we used a general likelihood approach (see Supplementary
information). Data on recruitment and on killing were log-trans-
formed and were assumed to have different error distribution (with
standard deviations s1 and s2, respectively). In general this resulted in
well-behaved and normally distributed residuals except in the case
when targets were pulsedwith a low peptide concentration. The latter
ﬁts resulted in a skewed distribution of the residuals (results not
shown). Discrimination between different models was done using
either the likelihood ratio test (LRT) or F-test for nested models
(Burnham and Anderson, 2002; Bates and Watts, 1988). Conﬁdence
intervals (CIs) were calculated by bootstrapping the data with 1000
simulations (Efron and Tibshirani, 1993). Fits of the data for PyV-
speciﬁc CD8+ T cell response were done as described previously
(Ganusov et al., 2007; Althaus et al., 2007). Fits of the data on virus
kinetics were done by log-transforming themodel predictions and the
data. All data ﬁttings were done in Mathematica 5.2 using the routine
FindMinimum.
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